Pharvaris Raises $115M in Share Offering Ahead of Key Clinical Data
Event summary
- Pharvaris priced an underwritten offering of 3.87 million ordinary shares at $29.68 per share, raising $115 million.
- Underwriters have a 30-day option to purchase an additional 581,199 shares.
- Proceeds will support clinical development and regulatory filings for bradykinin-mediated disease treatments.
- The offering is expected to close on May 11, 2026.
- Pharvaris is preparing marketing authorization applications for deucrictibant immediate-release capsule.
The big picture
Pharvaris' $115 million share offering comes as the company advances its pipeline of oral bradykinin B2 receptor antagonists, targeting unmet needs in hereditary and acquired angioedema. The raise positions Pharvaris to navigate key clinical and regulatory milestones, but competition in the bradykinin-mediated disease space and the need for sustained efficacy and safety data will shape its long-term prospects. The deal underscores the biopharmaceutical sector's reliance on strategic capital raises to fund late-stage development ahead of potential commercialization.
What we're watching
- Clinical Milestones
- The pace at which Pharvaris delivers topline data from its CHAPTER-3 and CREAATE Phase 3 studies will determine the trajectory of its lead candidates.
- Regulatory Pathway
- Whether Pharvaris can secure marketing authorization for deucrictibant immediate-release capsule in the first half of 2026 will be critical for its commercial strategy.
- Capital Deployment
- How Pharvaris allocates the $115 million in proceeds will signal its priorities between clinical development, regulatory filings, and potential expansion into new indications.
Related topics